Allumera shows significant improvements in appearance of skin compared to light

30-Nov-2010 - Norway

Photocure announced positive preliminary results from its consumer trial on Allumera™, demonstrating that the product can improve the appearance of skin. The RevitAll ™ study was designed to determine the ability of Allumera™ cream to improve the appearance of skin compared to illumination by light alone.

This prospective and controlled cosmetic study included 120 women of which 60 women received three applications of Allumera™ one month apart. The remaining 60 received light alone. The total study duration was five months. The four month at a presented today represent the results obtained two months after the last session. Subjects who received Allumera™ for one hour followed by illumination showed a time dependent and significant reduction in the appearance of pores (p<0.01), significant improvement in skin appearing more supple (p<0.05), and a significant increase in skin appearing firmer (p<0.05) compared to base line as well as light alone. In addition, there was a significant improvement in the appearance of even skin tone (p<0.05) compared to baseline. However, this improvement in the appearance of even skin tone did not reach statistical significance compared to light alone.

The majority of women receiving Allumera™ reported substantial benefits across important personal cosmetic evaluations measurements. Moreover, the data demonstrated excellent safety and tolerability. Allumera™ followed by illumination was well tolerated with few side effects and minimal down-time. No study participants in either group experienced side effect which caused withdrawal from the study.

The company plans to bring Allumera™ to the US aesthetic dermatology market via its newly established US subsidiary within the first half of 2011 and is preparing to present this study and others at key aesthetic dermatology meetings over the course of 2011. Allumera™ will offer a potential new convenient way for consumers to receive cosmetic benefits without significant down-time or other side effects.

Kjetil Hestdal, President & CEO of Photocure ASA noted, "This trial provides strong evidence for applications of our technology in dermatology. We have developed Allumera™ to enter the US dermatology market as an effective and tolerable product to improve the appearance of skin."

https://www.bionity.com/en/news/126729/allumera-shows-significant-improvements-in-appearance-of-skin-compared-to-light.html